FEDERAL Minister for Health Greg Hunt has announced the PBS funding of long-acting muscarinic antagonist Spiriva Respimat, from Boehringer Ingelheim (BI), for children six years and older with severe asthma.
Effective 01 Mar, the listing will positively impact on more than 30,000 children, BI said.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Feb 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Feb 19
